More Videos
- Pfizer's Chantix And Celebrex: Anti-Smoking "Double Play"?
- ASCO Countdown: Conference Season In Full Bloom
- Palatin Technologies: No Nose For Impotence
- Dendreon In Vegas, Lance Armstrong And Cancer Studies
- Eli Lilly's Ladies' Drug Campaign: Kind of Strange TV Ad?
- Reporters Barred from Ariad, Celgene, Cougar Roundtable?
- Amgen CEO To Shareholders: I Feel Your Pain, Too
- Amgen's Visit From The "Tooth Fairy" (By Way Of Root Canal?)
- Merck's Layoffs Show Pain Of Lower Drug Sales,Too Many Reps
- Pfizer "Re-Lighting" Chantix Ad Campaign For Smokers?
- Pfizer's Chantix And Celebrex: Anti-Smoking "Double Play"?
- Welcome To "Trading Chicago Hope"
- Your First Move For Monday May 19th
- Web Extra: Windy City Whale Watching
- Lightning Round OT: Schlumberger, Wellcare and More
- Chicago Turnaround Story?
- Surprise Friday – Guess Our Chicago Guest
- Measuring Google's Success
- Pops & Drops: Abbott Labs, Starbucks...
- Life Is Good In The Pits
- Chicago Ag Trades
- Market 360: The Best and Worst of the Week for US Equities, Commodities, Currencies, and More
- The Dow, S&P and NASDAQ are all positive for the week, with the NASDAQ in the lead gaining over 3%.
- Stocks Start to Hit a Wall: Here's What You Can Do
- Paulson: Economy Is Better But Housing Still a Threat
- Ryanair CEO Says Downturn Good for the Company
- Credit Problems Spreading Beyond Mortgages: FDIC
- Bonds Gain Following Weak Consumer Sentiment Reading
- Consumer Sentiment Falls To Lowest Level in 28 Years
- How To Prosper On Retiring Boomers
- Goldman Forecasts $141 Oil For Second Half of Year
 |
CNBC.com |
] management at the start of the Q and A portion of the biotech company's analyst meeting? Yep. Mark Schoenebaum from Bear Stearns [BSC
Loading...
(%)
]. When they get the mike, the analysts all state their names and the firms they work for. And as soon as Schoenebaum said, "Bear Stearns", Genentech CEO Art Levinson yells out, "You mean there's somebody from Bear Stearns still here?" The room erupted in laughter.
related content |
Schoenebaum came back with a quick retort, "You guys (the Genentech team) do great work," jokingly hinting he might need to butter them up for a job soon. Genentech's CFO, David Ebersman, used to be a sell-side analyst. By the way, I'll be doing a "First On CNBC" interview with Ebersman on "Closing Bell" at 3 p.m. ET today.
And then toward the end of the Q and A session an analyst gets the mike and once again prefaces his question by introducing himself, "Geoffrey Meacham with JPMorgan...soon to be the parent company, I guess, of Bear Stearns."
Laughter ensues. The meeting ends.
Questions? Comments?
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes